(Q35854816)

10 August 2017

0 references

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors (English)

1 reference

10 August 2017

Yoshitaka Seki

1

1 reference

10 August 2017

Noboru Yamamoto

2

1 reference

10 August 2017

Yosuke Tamura

3

1 reference

10 August 2017

Yasushi Goto

4

1 reference

10 August 2017

Takashi Shibata

5

1 reference

10 August 2017

Maki Tanioka

6

1 reference

10 August 2017

Hajime Asahina

7

1 reference

10 August 2017

Hiroshi Nokihara

8

1 reference

10 August 2017

Yasuhide Yamada

9

1 reference

10 August 2017

Takashi Shimamoto

10

1 reference

10 August 2017

Kazuo Noguchi

11

1 reference

10 August 2017

Tomohide Tamura

12

1 reference

10 August 2017

6 December 2011

1 reference

Cancer Chemotherapy and Pharmacology

10 August 2017

1 reference

10 August 2017

69

1 reference

10 August 2017

4

1 reference

10 August 2017

1099-1105

1 reference

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

The biology behind mTOR inhibition in sarcoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Current development of mTOR inhibitors as anticancer agents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Intracellular signal transduction pathway proteins as targets for cancer therapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

mTOR-targeted therapy of cancer with rapamycin derivatives

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

The TOR pathway: a target for cancer therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Targeting HIF-1 for cancer therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

11 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-011-1788-4

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-011-1788-4

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-011-1788-4

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3313018

mTOR inhibitors in the treatment of cancer

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22143378

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-011-1788-4

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22143378

1 reference